Skip to main content
. 2020 Apr 2;33(7):762–772. doi: 10.1111/tri.13601

Figure 4.

Figure 4

First‐line treatment for acute graft‐versus‐host disease. Responding centers (N = 75 of 75 participating centers). Relapse risk of underlying malignant disease.